Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

As Novo Nordisk A/S expands its presence in Massachusetts, the Danish pharmaceutical giant is also growing its partnerships ...

This week on Pipeline Moves, we kick off by looking at Novo Nordisk’s completion of a Phase III trial of liraglutide in ...

The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new ...

Biopharmaceutical company Korro Bio, Inc. (KRRO) announced Monday a collaboration with Danish healthcare company Novo Nordisk A/S ...

Novo Nordisk Inc. was sued Friday by five former employees who say the pharmaceutical company mismanages its $2.3 billion ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Novo Nordisk CEO Lars Jørgensen will testify about the high cost of Ozempic and Wegovy at an upcoming HELP Committee hearing on September 24th.

On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Partnership leverages Korro’s proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; ...